Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue eJHaem Année : 2022

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

Résumé

The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
Fichier principal
Vignette du fichier
2022 (eJHaem) Anti‐SARS‐CoV‐2 vaccines in recipient and or donor before allotransplant.pdf (203 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

inserm-03580755 , version 1 (18-02-2022)

Identifiants

Citer

Maxime Jullien, Marianne Coste‐burel, Beatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, et al.. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant. eJHaem, 2022, ahead of print. ⟨10.1002/jha2.398⟩. ⟨inserm-03580755⟩
130 Consultations
133 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More